Private Advisor Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.15M | Sell |
32,456
-11,904
| -27% | -$1.49M | 0.02% | 727 |
|
|
2025
Q4 | $5.41M | Sell |
44,360
-1,829
| -4% | -$210K | 0.03% | 595 |
|
|
2025
Q3 | $4.63M | Buy |
46,189
+8,498
| +23% | +$765K | 0.02% | 649 |
|
|
2025
Q2 | $3.13M | Sell |
37,691
-127,782
| -77% | -$10.2M | 0.02% | 760 |
|
|
2025
Q1 | $13.4M | Sell |
165,473
-33,349
| -17% | -$2.98M | 0.08% | 258 |
|
|
2024
Q4 | $17.9M | Sell |
198,822
-26,023
| -12% | -$2.52M | 0.1% | 187 |
|
|
2024
Q3 | $22.2M | Buy |
224,845
+1,530
| +0.7% | +$150K | 0.14% | 146 |
|
|
2024
Q2 | $20.7M | Sell |
223,315
-3,354
| -1% | -$301K | 0.14% | 141 |
|
|
2024
Q1 | $21.5M | Buy |
226,669
+6,551
| +3% | +$608K | 0.15% | 125 |
|
|
2023
Q4 | $19.7M | Buy |
220,118
+78,535
| +55% | +$5.83M | 0.15% | 129 |
|
|
2023
Q3 | $10.3M | Buy |
141,583
+69,390
| +96% | +$5.54M | 0.09% | 209 |
|
|
2023
Q2 | $6.02M | Buy |
72,193
+8,716
| +14% | +$729K | 0.05% | 341 |
|
|
2023
Q1 | $4.84M | Buy |
63,477
+23,627
| +59% | +$1.96M | 0.05% | 387 |
|
|
2022
Q4 | $816K | Sell |
39,850
-14,066
| -26% | -$1.14M | 0.04% | 421 |
|
|
2022
Q3 | $4.28M | Sell |
53,916
-6,284
| -10% | -$530K | 0.05% | 375 |
|
|
2022
Q2 | $4.47M | Buy |
60,200
+27,965
| +87% | +$2.1M | 0.04% | 445 |
|
|
2022
Q1 | $2.9M | Sell |
32,235
-12,506
| -28% | -$1.15M | 0.02% | 641 |
|
|
2021
Q4 | $5.01M | Buy |
44,741
+6,346
| +17% | +$765K | 0.04% | 456 |
|
|
2021
Q3 | $4.83M | Buy |
38,395
+7,441
| +24% | +$958K | 0.03% | 532 |
|
|
2021
Q2 | $4.19M | Buy |
30,954
+376
| +1% | +$49.4K | 0.04% | 471 |
|
|
2021
Q1 | $4.15M | Sell |
30,578
-15,108
| -33% | -$2.26M | 0.04% | 433 |
|
|
2020
Q4 | $6.43M | Buy |
45,686
+10,094
| +28% | +$1.29M | 0.07% | 287 |
|
|
2020
Q3 | $3.97M | Sell |
35,592
-49,914
| -58% | -$5.6M | 0.05% | 342 |
|
|
2020
Q2 | $9.57M | Buy |
85,506
+4,270
| +5% | +$421K | 0.13% | 159 |
|
|
2020
Q1 | $6.29M | Buy |
81,236
+62,238
| +328% | +$5.51M | 0.12% | 184 |
|
|
2019
Q4 | $1.81M | Buy |
18,998
+1,614
| +9% | +$140K | 0.03% | 570 |
|
|
2019
Q3 | $1.35M | Sell |
17,384
-846
| -5% | -$70.3K | 0.02% | 673 |
|
|
2019
Q2 | $1.6M | Buy |
18,230
+204
| +1% | +$17.4K | 0.03% | 554 |
|
|
2019
Q1 | $1.63M | Buy |
18,026
+1,304
| +8% | +$111K | 0.03% | 503 |
|
|
2018
Q4 | $1.2M | Sell |
16,722
-7,812
| -32% | -$629K | 0.03% | 528 |
|
|
2018
Q3 | $2.35M | Buy |
24,534
+6,411
| +35% | +$622K | 0.05% | 380 |
|
|
2018
Q2 | $1.74M | Buy |
18,123
+8,956
| +98% | +$823K | 0.03% | 321 |
|
|
2018
Q1 | $804K | Sell |
9,167
-5,106
| -36% | -$466K | 0.03% | 496 |
|
|
2017
Q4 | $1.22M | Sell |
14,273
-6,641
| -32% | -$556K | 0.05% | 369 |
|
|
2017
Q3 | $1.83M | Buy |
20,914
+1,448
| +7% | +$116K | 0.05% | 388 |
|
|
2017
Q2 | $1.5M | Buy |
19,466
+10,653
| +121% | +$756K | 0.04% | 429 |
|
|
2017
Q1 | $590K | Buy |
8,813
+3,246
| +58% | +$218K | 0.02% | 743 |
|
|
2016
Q4 | $353K | Buy |
5,567
+1,342
| +32% | +$82.8K | 0.01% | 879 |
|
|
2016
Q3 | $277K | Buy |
+4,225
| New | +$261K | 0.01% | 864 |
|
|
2015
Q3 | – | Sell |
-2,832
| Closed | -$238K | – | 1133 |
|
|
2015
Q2 | $238K | Sell |
2,832
-42
| -1% | -$3.27K | 0.01% | 873 |
|
|
2015
Q1 | $216K | Buy |
+2,874
| New | +$201K | 0.01% | 861 |
|
|
2014
Q4 | – | Sell |
-1,158
| Closed | -$60K | – | 1302 |
|
|
2014
Q3 | $60K | Buy |
+1,158
| New | +$59K | ﹤0.01% | 1027 |
|
|
2014
Q1 | – | Sell |
-61,248
| Closed | -$2.66M | – | 850 |
|
|
2013
Q4 | $2.66M | Buy |
+61,248
| New | +$2.54M | 0.3% | 73 |
|
Other funds holding XBI
Private Advisor Group's XBI Position: Q1 2026 in Review
Private Advisor Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 27% in Q1 2026, selling an estimated $1.49M and leaving 32,456 shares worth $4.15M. The position accounts for 0.02% of the portfolio, ranked #727.
Private Advisor Group first reported a position in XBI in Q4 2013 and has held it in 43 quarters since. The position peaked at $22.2M in Q3 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Private Advisor Group held 32,456 shares of State Street SPDR S&P Biotech ETF worth $4.15M as of Q1 2026.
- Private Advisor Group sold 11,904 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.49M.
- State Street SPDR S&P Biotech ETF made up 0.02% of Private Advisor Group's portfolio in Q1 2026, its #727 holding.
- Private Advisor Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2013 and has held it in 43 quarters since.
- Private Advisor Group's State Street SPDR S&P Biotech ETF position peaked at $22.2M in Q3 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.